<DOC>
	<DOCNO>NCT00081354</DOCNO>
	<brief_summary>Background : The incidence rate esophageal adenocarcinoma ( EAC ) rise 10 % per year past two decade rapidly increase cancer U.S. Barrett 's esophagus ( BE ) , metaplastic change normal squamous esophageal epithelium specialize intestinal-type columnar mucosa , increase risk EAC 30-125 , consider precursor lesion EAC . Individuals diagnose BE currently enter endoscopic surveillance program look dysplasia EAC . However , 5 % subject diagnose EAC previous diagnosis BE part surveillance program , alternative screen method need . Objectives : The primary goal project identify practical blood-based biomarker ( ) use screen test determine BE . Secondary goal project characterize germ-line tissue biomarkers associate BE , compare biomarkers non-BE patient without GERD . Tertiary goal explore association biomarkers blood tissue progression BE dysplasia EAC , assess stability proteomic patterns time . Eligibility : This study conduct among patient Barrett 's Esophagus Registry ( currently 206 registrant ) establish National Naval Medical Center ( NNMC ) Bethesda begin 1992 , well comparison group approximately 600 match non-BE patient endoscoped GI clinic NNMC condition . Design : Blood tissue sample collect well questionnaire data risk factor medication well GERD . Data analysis base primarily laboratory test newly collect esophageal biopsy , brush sample , blood sample , secondarily also include use archival tissue biopsy sample . Follow BE Registry patient include standard periodic surveillance endoscopy , additional blood sample , ascertainment disease status ( i.e. , progression ) . To distinguish BE versus non BE-patients case-control study , : ass predictability BE status serum proteomic pattern ; characterize esophageal biopsy brush sample select DNA alteration , RNA expression , proteomic profile ; genotype patient select polymorphism potentially associate BE ; compare blood tissue biomarkers non-BE patient without GERD ; explore association biomarkers progression BE dysplasia EAC ; assess proteomic pattern stability time BE patient .</brief_summary>
	<brief_title>Early Detection Barrett 's Esophagus</brief_title>
	<detailed_description>Background : The incidence rate esophageal adenocarcinoma ( EAC ) rise 10 % per year past two decade rapidly increase cancer U.S. Barrett 's esophagus ( BE ) , metaplastic change normal squamous esophageal epithelium specialize intestinal-type columnar mucosa , increase risk EAC 30-125 fold ( 1 ) , consider precursor lesion EAC . Individuals diagnose BE currently enter endoscopic surveillance program look dysplasia EAC . However , 5 % subject diagnose EAC previous diagnosis BE part surveillance program , alternative screen method need . Objectives : The primary goal project identify practical blood-based biomarker ( ) use screen test determine BE . Secondary goal project characterize germ line tissue biomarkers associate BE , compare biomarkers non-BE patient without GERD . Tertiary goal explore association biomarkers blood tissue progression BE dysplasia EAC , assess stability proteomic patterns time . Eligibility : This study conduct among patient Barretts Esophagus Registry ( currently 206 registrant ) establish National Naval Medical Center ( NNMC ) Bethesda begin 1992 well comparison group approximately 600 match non-BE patient endoscoped GI clinic NNMC condition . Design : Blood tissue sample collect well questionnaire data risk factor medication well GERD . Data analysis base primarily laboratory test newly collect esophageal biopsy , brush sample , blood sample , secondarily also include use archival tissue biopsy sample . Follow-up BE Registry patient include standard periodic surveillance endoscopy , additional blood sample , ascertainment disease status ( i.e , progression ) . To distinguish BE versus non-BE patient , : ( 1 ) ass predictability BE status serum proteomic patter ; ( 2 ) characterize esophageal biopsy brush sample select DNA alteration , RNA expression , proteomic profile ; ( 3 ) genotype patient select polymorphism potentially associate BE ; ( 4 ) compare blood tissue biomarkers non-BE patient without GERD ; ( 5 ) explore association biomarkers progression BE dysplasia EAC ; ( 6 ) ass proteomic pattern stability time BE patient .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Esophageal Diseases</mesh_term>
	<criteria>INCLUSION CRITERIA Inclusion criterion EGD study include : Greater equal 18 year age , presence GERD GERDlike symptom , presence BE , dysphagia , anemia , gastrointestinal bleeding , presence condition ( e.g. , dyspepsia ) merit endoscopic evaluation . EXCLUSION CRITERIA Exclusion criterion EGD study include : severe pulmonary cardiac disease , pregnancy , refusal , inability refusal give consent , age le 18 year participation NNMC Barrett 's esophagus cryotherapy protocol , malignancy nonmelanoma skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 30, 2017</verification_date>
	<keyword>Esophageal Adenocarcinoma</keyword>
	<keyword>Dysplasia</keyword>
	<keyword>Surveillance</keyword>
	<keyword>Proteomics</keyword>
	<keyword>SNP 's</keyword>
	<keyword>Barrett Esophagus</keyword>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>GERD</keyword>
	<keyword>Dysphagia</keyword>
	<keyword>Swallowing Difficulty</keyword>
</DOC>